These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 38060699)

  • 1. Safety and Efficacy of Biologic Therapies (Ustekinumab and Vedolizumab) in the Treatment of Inflammatory Bowel Disease (IBD): A Systematic Review.
    Ashraf H; Bodapati A; Hanif A; Okafor DK; Katyal G; Kaur G; Khan S
    Cureus; 2023 Nov; 15(11):e48338. PubMed ID: 38060699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of vedolizumab and ustekinumab as second biologic agent in achieving target outcomes in tumor necrosis factor antagonists experienced patients with inflammatory bowel disease (enroll-ex study).
    Alrashed F; Abdullah I; Alfadhli A; Shehab M
    Front Pharmacol; 2023; 14():1243080. PubMed ID: 37876726
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn's disease in patients with prior failure of anti-tumour necrosis factor treatment.
    Hyun HK; Zhang HS; Yu J; Kang EA; Park J; Park SJ; Park JJ; Kim TI; Kim WH; Cheon JH
    BMC Gastroenterol; 2022 Mar; 22(1):143. PubMed ID: 35346063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study.
    Garcia-Romero R; Martinez de Zabarte Fernandez JM; Pujol-Muncunill G; Donat-Aliaga E; Segarra-Cantón O; Irastorza-Terradillos I; Medina-Benitez E; Ruiz-Hernández CJ; Carrillo-Palau M; Ros-Arnal I; Rodriguez-Martínez A; Escartin-Madurga L; Gutiérrez-Junquera C; Vicente-Santamaría S; Velasco Rodriguez-Belvis M; Fernández-Fernández S; Alberto-Alonso JR; Montraveta M; Torres-Peral R; Navalon-Rubio M; Navas-López VM; Martin de Carpi J
    Eur J Pediatr; 2021 Sep; 180(9):3029-3038. PubMed ID: 33880650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No Benefit of Concomitant Immunomodulator Therapy on Efficacy of Biologics That Are Not Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases: A Meta-analysis.
    Yzet C; Diouf M; Singh S; Brazier F; Turpin J; Nguyen-Khac E; Meynier J; Fumery M
    Clin Gastroenterol Hepatol; 2021 Apr; 19(4):668-679.e8. PubMed ID: 32629124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab.
    Hu A; Kotze PG; Burgevin A; Tan W; Jess A; Li PS; Kroeker K; Halloran B; Panaccione R; Peyrin-Biroulet L; Ma C; Ananthakrishnan AN
    Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1366-1376.e2. PubMed ID: 32668338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy is not associated with improved rates of clinical or endoscopic remission in patients with inflammatory bowel disease treated with ustekinumab or vedolizumab: a retrospective study.
    Jeffrey AW; Picardo S; Menon S; So K; Venugopal K
    Ann Gastroenterol; 2023; 36(4):430-436. PubMed ID: 37396006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease.
    Bressler B; Jones J; In TSH; Lan T; Iconaru C; Marshall JK
    Adv Ther; 2023 Oct; 40(10):4421-4439. PubMed ID: 37507652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Safety of Ustekinumab and Vedolizumab in Older Patients with Inflammatory Bowel Disease: A Bicentric Cohort Study.
    Burgevin A; Caron B; Sasson A; Luc A; Netter P; Baumann C; Ananthakrishnan AN; Peyrin-Biroulet L
    J Clin Med; 2022 Nov; 11(23):. PubMed ID: 36498541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second-Line Biologic Therapy Following Tumor Necrosis Factor Antagonist Failure: A Real-World Propensity Score-Weighted Analysis.
    Ibing S; Cho JH; Böttinger EP; Ungaro RC
    Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2629-2638. PubMed ID: 36787837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Persistence of Successive Biologics in Patients With Inflammatory Bowel Disease: Findings From ROTARY.
    Krugliak Cleveland N; Ghosh S; Chastek B; Bancroft T; Candela N; Fan T; Umashankar K; Rubin DT
    Inflamm Bowel Dis; 2023 Oct; ():. PubMed ID: 37921344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease.
    Barré A; Colombel JF; Ungaro R
    Aliment Pharmacol Ther; 2018 Apr; 47(7):896-905. PubMed ID: 29430672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fecal transplantation for treatment of inflammatory bowel disease.
    Imdad A; Nicholson MR; Tanner-Smith EE; Zackular JP; Gomez-Duarte OG; Beaulieu DB; Acra S
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012774. PubMed ID: 30480772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic mechanisms behind a refractory state in inflammatory bowel disease.
    Goll R; Moe ØK; Johnsen KM; Meyer R; Friestad J; Gundersen MD; Kileng H; Johnsen K; Florholmen JR
    BMC Gastroenterol; 2022 Nov; 22(1):464. PubMed ID: 36384462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.
    Gisbert JP; Chaparro M
    J Crohns Colitis; 2020 Jun; 14(5):694-709. PubMed ID: 31777929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
    Solitano V; Facciorusso A; Jess T; Ma C; Hassan C; Repici A; Jairath V; Armuzzi A; Singh S
    Clin Gastroenterol Hepatol; 2023 Apr; 21(4):907-921.e2. PubMed ID: 35944832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual Biologic and Small Molecule Therapy for the Treatment of Refractory Pediatric Inflammatory Bowel Disease.
    Dolinger MT; Spencer EA; Lai J; Dunkin D; Dubinsky MC
    Inflamm Bowel Dis; 2021 Jul; 27(8):1210-1214. PubMed ID: 33125058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.
    Peyrin-Biroulet L; Arkkila P; Armuzzi A; Danese S; Guardiola J; Jahnsen J; Lees C; Louis E; Lukáš M; Reinisch W; Roblin X; Jang M; Byun HG; Kim DH; Lee SJ; Atreya R
    BMC Gastroenterol; 2022 Jun; 22(1):291. PubMed ID: 35676620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ustekinumab or Vedolizumab after Failure of Anti-TNF Agents in Crohn's Disease: A Review of Comparative Effectiveness Studies.
    Sharip MT; Nishad N; Pillay L; Goordoyel N; Goerge S; Subramanian S
    J Clin Med; 2024 Apr; 13(8):. PubMed ID: 38673459
    [No Abstract]   [Full Text] [Related]  

  • 20. Effectiveness and Safety of Ustekinumab in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
    Honap S; Meade S; Ibraheim H; Irving PM; Jones MP; Samaan MA
    Dig Dis Sci; 2022 Mar; 67(3):1018-1035. PubMed ID: 33723700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.